• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    FDA Approval for issued to TARSUS PHARMACEUTICALS, INC

    7/25/23 4:29:16 PM ET
    $TARS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $TARS alert in real time by email
    New Drug Application (NDA): 217603
    Company: TARSUS PHARMACEUTICALS, INC
    • Email

    Products on NDA 217603

    Drug Name Active Ingredients Strength Dosage Form/Route Marketing Status TE Code RLD RS
    SOLUTION; OPHTHALMIC Prescription None No No
    XDEMVY LOTILANER 0.25% SOLUTION/DROPS;OPHTHALMIC Prescription None No No

    Approval Date(s) and History, Letters, Labels, Reviews for NDA 217603

    Supplements
    Action Date Submission Supplement Categories or Approval Type Letters, Reviews, Labels, Patient Package Insert Note Url
    07/24/2023 SUPPL-1 Letter (PDF)

    Label is not available on this site.

    https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/217603Orig1s000ltr.pdf
    Get the next $TARS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TARS

    DatePrice TargetRatingAnalyst
    6/2/2025$75.00Outperform
    Oppenheimer
    5/27/2025$72.00Buy
    H.C. Wainwright
    11/20/2023$19.00Neutral
    Goldman
    7/18/2023$44.00Outperform
    William Blair
    5/18/2023Buy
    Guggenheim
    8/1/2022$40.00Overweight
    Barclays
    12/21/2021$40.00Buy
    HC Wainwright & Co.
    11/23/2021$55.00Outperform
    Oppenheimer
    More analyst ratings

    $TARS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for XDEMVY issued to TARSUS PHARMACEUTICALS, INC.

      Submission status for TARSUS PHARMACEUTICALS, INC.'s drug XDEMVY (ORIG-1) with active ingredient LOTILANER has changed to 'Approval' on 07/24/2023. Application Category: NDA, Application Number: 217603, Application Classification: Type 1 - New Molecular Entity

      7/25/23 4:35:13 PM ET
      $TARS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • FDA Approval for issued to TARSUS PHARMACEUTICALS, INC.

      Submission status for TARSUS PHARMACEUTICALS, INC.'s drug (ORIG-1) with active ingredient has changed to 'Approval' on 07/24/2023. Application Category: NDA, Application Number: 217603, Application Classification: Type 1 - New Molecular Entity

      7/25/23 4:35:13 PM ET
      $TARS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • FDA Approval for issued to TARSUS PHARMACEUTICALS, INC

      Submission status for TARSUS PHARMACEUTICALS, INC's drug (SUPPL-1) with active ingredient has changed to 'Approval' on 07/24/2023. Application Category: NDA, Application Number: 217603, Application Classification: Type 1 - New Molecular Entity

      7/25/23 4:29:16 PM ET
      $TARS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care